Código QR (código de barras bidimensional)

Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma

Background & Aims: The RESORCE trial confirmed regorafenib as a second-line treatment for advanced hepatocellular carcinoma (HCC) in patients who tolerated sorafenib. However, its safety and efficacy in patients with diverse treatment histories remain unknown. The REGAIN study sought to assess r...

Fuld beskrivelse

Na minha lista:
Principais autores: Keisuke Koroki, Sadahisa Ogasawara, Sae Yumita, Miyuki Nakagawa, Hiroaki Kanzaki, Kazufumi Kobayashi, Masanori Inoue, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Yuki Shiko, Yoshihito Ozawa, Yosuke Inaba
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier 2025-10-01
Serier:JHEP Reports
Fag:
Hepatocellular carcinoma
Regorafenib
RESORCE trial
Randomized controlled trial
Online adgang:http://www.sciencedirect.com/science/article/pii/S2589555925001879
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker